23andMe Considers Strategic Shift: Lemonaid Telehealth Business on the Potential Auction Block
In a strategic pivot amid ongoing challenges, 23andMe is seeking to offload its virtual care business, which it originally acquired just two years ago. According to exclusive insights from Business Insider, the genetic testing company is actively exploring potential buyers for this digital healthcare segment. The move comes as 23andMe continues to navigate a complex and competitive landscape, looking to streamline its operations and potentially recoup investments made during a period of significant expansion. The virtual care business, initially seen as a promising addition to the company's portfolio, now appears to be a potential asset for divestment. This development underscores the rapidly evolving nature of digital health services and the ongoing challenges faced by companies attempting to diversify their healthcare technology offerings. As 23andMe reassesses its strategic direction, the potential sale signals a careful reevaluation of its business model and future growth strategies.